To include your compound in the COVID-19 Resource Center, submit it here.

Afinitor everolimus: Phase III data

The double-blind, international Phase III EXIST-1 trial in 117 patients showed that Afinitor met the primary endpoint of significantly improving overall SEGA response rate vs. placebo. Specifically, 35% of patients receiving Afinitor (n=78) had a >=50% reduction

Read the full 378 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE